Although subjects with an early disease stage (i.e., healthy controls with Aβ PET+) were not enrolled in this study, it may be reasonable to pursue AβpE3−40/t-tau as a potential predictor of cerebral Aβ deposition in population-based screening for high-risk individuals before AD symptom onset. This evidence concerns the gene MAPT and Alzheimer disease.